Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma: A Single-Arm, Open-Label, Multicenter, Phase II Study
Authors not listed
Sun Yat-sen University · 2025
Abstract
This is a single- arm, open-label, multicenter, phase II study to evaluate Acalabrutinib plus Rituximab for the treatment of elderly or low- to intermediate-risk younger untreated mantle cell lymphoma
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-06 MST
Cite this
APA
Anonymous. (2025). Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. <em>Sun Yat-sen University</em>. https://clinicaltrials.gov/study/NCT06846489
Vancouver
Anonymous. Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma: A Single-Arm, Open-Label, Multicenter, Phase II Study. Sun Yat-sen University. 2025.
BibTeX
@misc{anon2025Acalab,
title = {Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell Lymphoma: A Single-Arm, Open-Label, Multicenter, Phase II Study},
author = {Anonymous},
journal = {Sun Yat-sen University},
year = {2025},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University College, London 2023
Open access · US-GOV
Phase II Study of Acalabrutinib and Rituximab for Elderly or Frail Patients With Previously Untreated Mantle Cell Lymphoma
M.D. Anderson Cancer Center 2021
Open access · US-GOV
A Phase II Study of Acalabrutinib Plus Rituximab in Previously Untreated Elderly Patients With Mantle Cell Lymphoma
Xiaohui He 2025
Open access · US-GOV
A Multicenter, Prospective Phase Ⅱ Clinical Study of R-mini-MCOP(Rituximab / Mitoxantrone Liposome / Cyclophosphamide / Vincristine / Prednisone) in the Treatment of Elderly, Previously Untreated Diffuse Large B-cell Lymphoma
Huiqiang Huang 2020
Open access · US-GOV
Phase Ib/II Study of Toripalimab In Combination With Rituximab Followed by R-CHOP Regimen (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) for Elderly Naïve Patients With Diffuse Large B-cell Lymphoma
Fondazione Italiana Linfomi - ETS 2007
Open access · US-GOV
Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of Treatment With Lenalidomide Plus R-CHOP21 (LR-CHOP21) for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma (DLBCL)
Sun Yat-sen University 2026
Open access · US-GOV